Deneddylation of ribosomal proteins promotes synergy between MLN4924 and chemotherapy to elicit complete therapeutic responses.

[1]  T. Maehama,et al.  Nucleolar stress: Molecular mechanisms and related human diseases , 2023, Cancer science.

[2]  T. Furukawa,et al.  Nucleolar Stress Response via Ribosomal Protein L11 Regulates Topoisomerase Inhibitor Sensitivity of P53-Intact Cancers , 2022, International journal of molecular sciences.

[3]  S. Goldsmith,et al.  Selinexor therapy for multiple myeloma and non-Hodgkin lymphomas , 2022, Current opinion in oncology.

[4]  D. Faller,et al.  Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML , 2022, Blood advances.

[5]  J. Bartek,et al.  Targeting Ribosome Biogenesis in Cancer: Lessons Learned and Way Forward , 2022, Cancers.

[6]  J. Bauman,et al.  Targeted CUL4A inhibition synergizes with cisplatin to yield long-term survival in models of head and neck squamous cell carcinoma through a DDB2-mediated mechanism , 2022, Cell Death & Disease.

[7]  A. Carcaboso,et al.  Treatment of Retinoblastoma: What Is the Latest and What Is the Future , 2022, Frontiers in Oncology.

[8]  A. Santoni,et al.  Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition , 2021, Cell Death & Disease.

[9]  Tao Yu,et al.  Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. , 2021, Cancer cell.

[10]  C. Rudin,et al.  Protein neddylation as a therapeutic target in pulmonary and extrapulmonary small cell carcinomas , 2021, Genes & development.

[11]  K. Venkatakrishnan,et al.  Asia‐inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial , 2021, Clinical and translational science.

[12]  J. Bartek,et al.  Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer. , 2020, Trends in cancer.

[13]  D. Longley,et al.  Pevonedistat (MLN4924): mechanism of cell death induction and therapeutic potential in colorectal cancer , 2020, Cell Death Discovery.

[14]  Tao Yu,et al.  Functional genomics identifies new synergistic therapies for retinoblastoma , 2020, Oncogene.

[15]  J. Greenblatt,et al.  Nucleolar RNA polymerase II drives ribosome biogenesis , 2020, Nature.

[16]  G. Mills,et al.  Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. , 2020, Cancer cell.

[17]  C. Hoogenraad,et al.  Global site-specific neddylation profiling reveals that NEDDylated cofilin regulates actin dynamics , 2020, Nature Structural & Molecular Biology.

[18]  Tao Yu,et al.  Preclinical studies reveal MLN4924 is a promising new retinoblastoma therapy , 2020, Cell Death Discovery.

[19]  P. Maeder,et al.  Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity” , 2019, Progress in Retinal and Eye Research.

[20]  K. Venkatakrishnan,et al.  Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies , 2019, British journal of clinical pharmacology.

[21]  Yu Zeng,et al.  An overactive neddylation pathway serves as a therapeutic target and MLN4924 enhances the anticancer activity of cisplatin in pancreatic cancer. , 2019, Oncology letters.

[22]  C. Larsson,et al.  Proteomics identifies neddylation as a potential therapy target in small intestinal neuroendocrine tumors , 2019, Oncogene.

[23]  E. Leich,et al.  The NEDD8-activating enzyme inhibitor MLN4924 sensitizes a TNFR1+ subgroup of multiple myeloma cells for TNF-induced cell death , 2019, Cell Death & Disease.

[24]  T. Graeber,et al.  Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies. , 2019, Cancer cell.

[25]  L. Skalniak,et al.  Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists , 2019, Cancers.

[26]  T. Hideshima,et al.  A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity , 2018, Leukemia.

[27]  Yi Sun,et al.  Protein neddylation and its alterations in human cancers for targeted therapy. , 2018, Cellular signalling.

[28]  Michael T. McManus,et al.  The Transcriptionally Permissive Chromatin State of Embryonic Stem Cells Is Acutely Tuned to Translational Output. , 2018, Cell stem cell.

[29]  Z. Dong,et al.  Neddylation inhibitor MLN4924 induces G2 cell cycle arrest, DNA damage and sensitizes esophageal squamous cell carcinoma cells to cisplatin. , 2017, Oncology letters.

[30]  J. Yun,et al.  Promoting tumorigenesis in nasopharyngeal carcinoma, NEDD8 serves as a potential theranostic target , 2017, Cell Death & Disease.

[31]  Z. Ni,et al.  Properties of STAT1 and IRF1 enhancers and the influence of SNPs , 2017, BMC Molecular Biology.

[32]  T. Kohno,et al.  GRWD1 negatively regulates p53 via the RPL11–MDM2 pathway and promotes tumorigenesis , 2017, EMBO reports.

[33]  Wenyi Wei,et al.  Neddylation E2 UBE2F Promotes the Survival of Lung Cancer Cells by Activating CRL5 to Degrade NOXA via the K11 Linkage , 2016, Clinical Cancer Research.

[34]  C. Slingluff,et al.  Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma , 2016, EBioMedicine.

[35]  G. Mulligan,et al.  A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma , 2016, Investigational New Drugs.

[36]  A. Lamond,et al.  The NEDD8 inhibitor MLN4924 increases the size of the nucleolus and activates p53 through the ribosomal-Mdm2 pathway , 2016, Oncogene.

[37]  D. Durocher,et al.  High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities , 2015, Cell.

[38]  Meagan E. Sullender,et al.  Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9 , 2015, Nature Biotechnology.

[39]  G. Mulligan,et al.  Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma , 2015, Clinical Cancer Research.

[40]  Jeffrey W. Clark,et al.  Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors , 2015, Clinical Cancer Research.

[41]  P. Chen,et al.  The novel protective role of P27 in MLN4924-treated gastric cancer cells , 2015, Cell Death and Disease.

[42]  F. Zhan,et al.  NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma , 2015, Clinical Cancer Research.

[43]  B. Smith,et al.  MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors , 2015, Cell Death and Differentiation.

[44]  Stephen P. Jackson,et al.  Ubiquitylation, neddylation and the DNA damage response , 2015, Open Biology.

[45]  M. Peter,et al.  Protein neddylation: beyond cullin–RING ligases , 2014, Nature Reviews Molecular Cell Biology.

[46]  Yi Sun,et al.  Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy. , 2014, Antioxidants & redox signaling.

[47]  Neville E. Sanjana,et al.  Improved vectors and genome-wide libraries for CRISPR screening , 2014, Nature Methods.

[48]  Q. Gao,et al.  Overactivated neddylation pathway as a therapeutic target in lung cancer. , 2014, Journal of the National Cancer Institute.

[49]  G. Tonon,et al.  RESCUE OF HIPPO CO-ACTIVATOR YAP1 TRIGGERS DNA DAMAGE-INDUCED APOPTOSIS IN HEMATOLOGICAL CANCERS , 2014, Nature Medicine.

[50]  E. Lightcap,et al.  Nedd8-Activating Enzyme Inhibitor MLN4924 Provides Synergy with Mitomycin C through Interactions with ATR, BRCA1/BRCA2, and Chromatin Dynamics Pathways , 2014, Molecular Cancer Therapeutics.

[51]  M. Bohnsack,et al.  The 5S RNP Couples p53 Homeostasis to Ribosome Biogenesis and Nucleolar Stress , 2013, Cell reports.

[52]  A. Jazaeri,et al.  Overcoming Platinum Resistance in Preclinical Models of Ovarian Cancer Using the Neddylation Inhibitor MLN4924 , 2013, Molecular Cancer Therapeutics.

[53]  E. Jonasch,et al.  DDX3 regulates DNA damage-induced apoptosis and p53 stabilization. , 2013, Biochimica et biophysica acta.

[54]  S. Beausoleil,et al.  Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer , 2013, Clinical Cancer Research.

[55]  R. Weiss,et al.  A novel p21 attenuator which is structurally related to sorafenib , 2013, Cancer biology & therapy.

[56]  B. Wasylyk,et al.  The NEDD8 conjugation pathway regulates p53 transcriptional activity and head and neck cancer cell sensitivity to ionizing radiation. , 2012, International journal of oncology.

[57]  B. Mahata,et al.  Recruitment of RPL11 at promoter sites of p53-regulated genes upon nucleolar stress through NEDD8 and in an Mdm2-dependent manner , 2012, Oncogene.

[58]  Yi Sun,et al.  The p21-Dependent Radiosensitization of Human Breast Cancer Cells by MLN4924, an Investigational Inhibitor of NEDD8 Activating Enzyme , 2012, PloS one.

[59]  Usha Narayanan,et al.  Treatment-emergent mutations in NAEβ confer resistance to the NEDD8-activating enzyme inhibitor MLN4924. , 2012, Cancer cell.

[60]  B. Gallie,et al.  Regulation of p14ARF expression by miR-24: a potential mechanism compromising the p53 response during retinoblastoma development , 2012, BMC Cancer.

[61]  J. Wrana,et al.  Established and New Mouse Models Reveal E2f1 and Cdk2 Dependency of Retinoblastoma and Expose Strategies to Block Tumor Initiation , 2012, Oncogene.

[62]  M. Huang,et al.  Inhibition of the Nedd8 System Sensitizes Cells to DNA Interstrand Cross-linking Agents , 2012, Molecular Cancer Research.

[63]  Z. Darżynkiewicz,et al.  Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin/topotecan, mitoxantrone, or etoposide , 2012, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[64]  S. Lonial,et al.  MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells. , 2011, Blood.

[65]  E. Cho,et al.  Phosphorylation of von Hippel-Lindau protein by checkpoint kinase 2 regulates p53 transactivation , 2011, Cell cycle.

[66]  Michael J. Emanuele,et al.  Global Identification of Modular Cullin-RING Ligase Substrates , 2011, Cell.

[67]  E. Lightcap,et al.  Quantitative Proteomic Analysis of Cellular Protein Modulation upon Inhibition of the NEDD8-Activating Enzyme by MLN4924 , 2011, Molecular & Cellular Proteomics.

[68]  K. Mimori,et al.  Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11 , 2011, Nature Medicine.

[69]  Lijun Jia,et al.  Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression. , 2011, Neoplasia.

[70]  H. Masumoto,et al.  RNA content in the nucleolus alters p53 acetylation via MYBBP1A , 2011, The EMBO journal.

[71]  Ya‐Wen Cheng,et al.  Reduced p21WAF1/CIP1 via Alteration of p53-DDX3 Pathway Is Associated with Poor Relapse-Free Survival in Early-Stage Human Papillomavirus–Associated Lung Cancer , 2011, Clinical Cancer Research.

[72]  Anindya Dutta,et al.  NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. , 2010, Cancer research.

[73]  M. Dai,et al.  Ribosomal Protein L11 Associates with c-Myc at 5 S rRNA and tRNA Genes and Regulates Their Expression* , 2010, The Journal of Biological Chemistry.

[74]  Yanping Zhang,et al.  Signaling to p53: ribosomal proteins find their way. , 2009, Cancer cell.

[75]  Geng-Hung Liu,et al.  Regulation of nucleolar signalling to p53 through NEDDylation of L11 , 2009, EMBO reports.

[76]  Amanda Doucette,et al.  An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer , 2009, Nature.

[77]  K. Lam,et al.  High throughput screening of a small molecule one-bead-one-compound combinatorial library to identify attenuators of p21 as chemotherapy sensitizers , 2008, Cancer biology & therapy.

[78]  Z. Darżynkiewicz,et al.  Kinetics of histone H2AX phosphorylation and Chk2 activation in A549 cells treated with topotecan and mitoxantrone in relation to the cell cycle phase , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[79]  A. Iavarone,et al.  The HECT-domain ubiquitin ligase Huwe1 controls neural differentiation and proliferation by destabilizing the N-Myc oncoprotein , 2008, Nature Cell Biology.

[80]  R. Seong,et al.  BAF60a Interacts with p53 to Recruit the SWI/SNF Complex* , 2008, Journal of Biological Chemistry.

[81]  D. Xirodimas,et al.  Ribosomal proteins are targets for the NEDD8 pathway , 2008, EMBO reports.

[82]  J. Takahashi,et al.  Interpretation of the mouse electroretinogram , 2007, Documenta Ophthalmologica.

[83]  Yi Tang,et al.  Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. , 2006, Molecular cell.

[84]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[85]  E. Cho,et al.  p53 stabilization and transactivation by a von Hippel-Lindau protein. , 2006, Molecular cell.

[86]  P. Raychaudhuri,et al.  Cul4A and DDB1 Associate with Skp2 To Target p27Kip1 for Proteolysis Involving the COP9 Signalosome , 2006, Molecular and Cellular Biology.

[87]  Z. Darżynkiewicz,et al.  Assessment of ATM phosphorylation on Ser‐1981 induced by DNA topoisomerase I and II inhibitors in relation to Ser‐139‐histone H2AX phosphorylation, cell cycle phase, and apoptosis , 2005, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[88]  M. Takagi,et al.  Regulation of p53 Translation and Induction after DNA Damage by Ribosomal Protein L26 and Nucleolin , 2005, Cell.

[89]  M. Pagano,et al.  Role of the SCFSkp2 Ubiquitin Ligase in the Degradation of p21Cip1 in S Phase* , 2003, Journal of Biological Chemistry.

[90]  D. Livingston,et al.  MYC recruits the TIP60 histone acetyltransferase complex to chromatin , 2003, EMBO reports.

[91]  J. Choe,et al.  SWI/SNF Complex Interacts with Tumor Suppressor p53 and Is Necessary for the Activation of p53-mediated Transcription* , 2002, The Journal of Biological Chemistry.

[92]  A. Shevchenko,et al.  Promotion of NEDD8-CUL1 Conjugate Cleavage by COP9 Signalosome , 2001, Science.

[93]  John Calvin Reed,et al.  Bax is a transcriptional target and mediator of c-myc-induced apoptosis. , 2000, Cancer research.

[94]  Y. Xiong,et al.  Human CUL-1, but not other cullin family members, selectively interacts with SKP1 to form a complex with SKP2 and cyclin A. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[95]  L. Liu,et al.  Processing of topoisomerase I cleavable complexes into DNA damage by transcription. , 1997, Nucleic acids research.

[96]  I. Kill.  Localisation of the Ki-67 antigen within the nucleolus. Evidence for a fibrillarin-deficient region of the dense fibrillar component. , 1996, Journal of cell science.

[97]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[98]  K. Helin,et al.  Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation. , 1993, Genes & development.

[99]  C. Shields,et al.  Retinoblastoma , 1992, Nature Reviews Disease Primers.

[100]  P. Sonneveld,et al.  Multiple myeloma , 2017, Nature Reviews Disease Primers.

[101]  U. Narayanan,et al.  Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. , 2013, Cancer research.

[102]  Hua Li,et al.  Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. , 2012, Cancer research.

[103]  Joseph Locker,et al.  Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/− mice , 2010, Nature Genetics.